Diagonal Bio

On 26 September 2024, the exercise period for warrants of series TO 1, which were issued in connection with Diagonal’s rights issue of units earlier in 2024, ended. As a result of the warrant exercise, 77.794 new shares have now been registered with the Swedish Companies Registration Office. The total number of shares in the Company after the exercise of warrants of series TO 1 amount to 400.714.213 and the share capital amounts to SEK 3.998.354,2.

Conversion of interim shares to ordinary shares takes place around 11 October 2024 and ordinary shares are expected to be visible on each subscriber's depository account approximately two banking days thereafter.

For more information about the TO 1, please contact:

Sedermera Corporate Finance AB
Phone: +46 (0)40 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se

For more information, please contact:

Karin Wehlin, CEO
Phone: +46 (0)70 305 24 88
E-mail: kw@diagonalbio.com 

Certified Adviser

Svensk Kapitalmarknadsgranskning AB
E-mail: ca@skmg.se 

About Diagonal Bio

Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.